#BEGIN_DRUGCARD DB00977

# AHFS_Codes:
Not Available

# ATC_Codes:
G03CA01

# Absorption:
Rapid and complete absorption follows oral intake of ethinyl estradiol (bioavailability 43%).

# Biotransformation:
Hepatic. Quantitatively, the major metabolic pathway for ethinyl estradiol, both in rats and in humans, is aromatic hydroxylation, as it is for the natural estrogens.

# Brand_Mixtures:
Alesse (Ethinyl Estradiol + Levonorgestrel)
Apri (Ethinyl Estradiol + desogestrel)
Aviane (Ethinyl Estradiol + Levonorgestrel)
Brevicon (Ethinyl Estradiol + Norethindrone)
Cyclen (Ethinyl Estradiol + Norgestimate)
Demulen (Ethinyl Estradiol + Ethynodiol Diacetate)
Desogen (Ethinyl Estradiol + desogestrel)
Diane-35 (Cyproterone Acetate + Ethinyl Estradiol)
Evra (Ethinyl Estradiol + Norelgestromin)
Femhrt 1/5 (Ethinyl Estradiol + Norethindrone Acetate)
Femodene (Ethinyl Estradiol + gestodene)
Femodette (Ethinyl Estradiol + gestodene)
Jolessa (Ethinyl Estradiol + Levonorgestrel)
Junel (norethindrone acetate+ Ethinyl Estradiol)
Kariva (Ethinyl Estradiol + desogestrel)
Lessina (Ethinyl Estradiol + Levonorgestrel)
Lo-Femenal (Ethinyl Estradiol + Norgestrel)
Loestrin (Ethinyl Estradiol + Norethindrone Acetate)
Lutera (Ethinyl Estradiol + Levonorgestrel)
Lybrel (Ethinyl Estradiol + Levonorgestrel)
Marvelon (Desogestrel + Ethinyl Estradiol)
Mercilon (Ethinyl Estradiol + desogestrel)
Microgestin (norethindrone acetate+ Ethinyl Estradiol)
Min-Ovral (Ethinyl Estradiol + Levonorgestrel)
Minestrin 1/20 (Ethinyl Estradiol + Norethindrone Acetate)
Minulet (Ethinyl Estradiol + gestodene)
Mircette (Ethinyl Estradiol + desogestrel)
Neo Mens Tab (Ethinyl Estradiol + Ethisterone)
Nuvaring (Ethinyl Estradiol + Etonogestrel)
Ocella (Drospirenone + Ethinyl Estradiol)
Ortho (Ethinyl Estradiol + Norethindrone)
Ortho-Cept (Desogestrel + Ethinyl Estradiol)
Ovcon (Ethinyl Estradiol + Norethindrone)
Ovral (Ethinyl Estradiol + Norgestrel)
Preven (Ethinyl Estradiol + Levonorgestrel)
Quartette (Levonorgestrel/Ethinyl Estradiol + Ethinyl Estradiol)
Quasense (Ethinyl Estradiol + Levonorgestrel)
Seasonale (Ethinyl Estradiol + Levonorgestrel)
Seasonique (Ethinyl Estradiol + Levonorgestrel)
Select 1/35 (Ethinyl Estradiol + Norethindrone)
Sronyx (Ethinyl Estradiol + Levonorgestrel)
Synphasic (Ethinyl Estradiol + Norethindrone)
Tri-Cyclen (Ethinyl Estradiol + Norgestimate)
Tri-Cyclen Lo (Ethinyl Estradiol + Norgestimate)
Triphasil (Ethinyl Estradiol + Levonorgestrel)
Triquilar (Ethinyl Estradiol + Levonorgestrel)
Yasmin (Drospirenone + Ethinyl Estradiol)
Yasminelle (Drospirenone + Ethinyl Estradiol)
Yaz (Drospirenone + Ethinyl Estradiol)
Zarah (Drospirenone + Ethinyl Estradiol)

# Brand_Names:
Estinyl

# CAS_Registry_Number:
57-63-6

# ChEBI_ID:
4903

# Chemical_Formula:
C20H24O2

# Chemical_IUPAC_Name:
(1S,10R,11S,14R,15S)-14-ethynyl-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-2(7),3,5-triene-5,14-diol

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
28231

# Description:
A semisynthetic alkylated estradiol with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally and is often used as the estrogenic component in oral contraceptives [PubChem]. Ethinyl estradiol is marketed mostly as a combination oral contraceptive under several brand names such as Alesse, Tri-Cyclen, Triphasil, and Yasmin. The FDA label includes a black box warning that states that combination oral contraceptives should not be used in women over 35 years old who smoke due to the increased risk of serious cardiovascular side effects.

# Dosage_Forms:
Cream	Intravaginal
Insert, extended release	Transdermal
Tablet	Oral

# Drug_Category:
Estrogens

# Drug_Interactions:
Acenocoumarol	Increased thrombotic risk due to estrogen
Aminophylline	The contraceptive increases the effect and toxicity of theophylline
Amobarbital	This product may cause a slight decrease of contraceptive effect
Amoxicillin	This anti-infectious agent could decrease the effect of the oral contraceptive
Ampicillin	This anti-infectious agent could decrease the effect of the oral contraceptive
Amprenavir	Ritonavir could decrease the contraceptive efficacy
Anisindione	Increased thrombotic risk due to estrogen
Aprepitant	Aprepitant could decrease the effect of the oral contraceptive
Aprobarbital	This product may cause a slight decrease of contraceptive effect
Artemether	Artemether may decrease the effectiveness of ethinyl estradiol by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy.
Azlocillin	This anti-infectious agent could decrease the effect of the oral contraceptive
Aztreonam	This anti-infectious agent could decrease the effect of the oral contraceptive
Bacampicillin	This anti-infectious agent could decrease the effect of the oral contraceptive
Bendamustine	Increases levels of bendamustine by decreasing metabolism. Ethinyl Estradiol is a CYP1A2 inhibitor and concurrent administration may result in elevated plasma concentrations of bendamustine.
Bosentan	Bosentan may decrease the contraceptive effect of ethinyl estradiol. Hormonal contraception should not be relied on alone during concomitant therapy with bosentan.
Butabarbital	This product may cause a slight decrease of contraceptive effect
Butalbital	This product may cause a slight decrease of contraceptive effect
Butethal	This product may cause a slight decrease of contraceptive effect
Carbamazepine	Carbamazepine may decrease the contraceptive effect of ethinyl estradiol. Hormonal contraception should not be relied on alone during concomitant therapy with carbamazepine.
Clavulanate	This anti-infectious agent could decrease the effect of the oral contraceptive
Cloxacillin	This anti-infectious agent could decrease the effect of the oral contraceptive
Colesevelam	Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Estrogens). Administer estrogen-based oral contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness. Ethinyl estradiol patches and vaginal rings may also be somewhat impacted by this interaction, though the extent and significance of such an interaction is uncertain.
Cyclacillin	This anti-infectious agent could decrease the effect of the oral contraceptive
Cyclosporine	The contraceptive increases the effect and toxicity of cyclosporine
Demeclocycline	This anti-infectious agent could decrease the effect of the oral contraceptive
Dicloxacillin	This anti-infectious agent could decrease the effect of the oral contraceptive
Dicumarol	Increased thrombotic risk due to estrogen
Doxycycline	Doxycycline may decrease the contraceptive effect of ethinyl estradiol.
Dyphylline	The contraceptive increases the effect and toxicity of theophylline
Eltrombopag	Affects hepatic CYP1A2 metabolism, increases Eltrombopag level or affect.
Ethotoin	This product may cause a slight decrease of contraceptive effect
Etoricoxib	Etoricoxib may increase the levels of ethinyl estradiol.
Flucloxacillin	This anti-infectious agent could decrease the effect of the oral contraceptive
Fosphenytoin	This product may cause a slight decrease of contraceptive effect
Griseofulvin	This product may cause a slight decrease of contraceptive effect
Heptabarbital	This product may cause a slight decrease of contraceptive effect
Hetacillin	This anti-infectious agent could decrease the effect of the oral contraceptive
Hexobarbital	This product may cause a slight decrease of contraceptive effect
Ketoconazole	This anti-infectious agent could decrease the effect of the oral contraceptive
Lamotrigine	The oral contraceptive decreases the effect of lamotrigine
Mephenytoin	This product may cause a slight decrease of contraceptive effect
Methacycline	This anti-infectious agent could decrease the effect of the oral contraceptive
Methohexital	This product may cause a slight decrease of contraceptive effect
Methylphenobarbital	This product may cause a slight decrease of contraceptive effect
Meticillin	This anti-infectious agent could decrease the effect of the oral contraceptive
Mezlocillin	This anti-infectious agent could decrease the effect of the oral contraceptive
Minocycline	This anti-infectious agent could decrease the effect of the oral contraceptive
Modafinil	Modafinil may decrease the contraceptive effect of ethinyl estradiol. Hormonal contraception should not be solely relied on during concomitant therapy with modafinil.
Nafcillin	This anti-infectious agent could decrease the effect of the oral contraceptive
Nelfinavir	Ritonavir could decrease the contraceptive efficacy
Oxacillin	This anti-infectious agent could decrease the effect of the oral contraceptive
Oxcarbazepine	Oxcarbazepine may decrease the contraceptive effect of ethinyl estradiol. Hormonal contraception should not be solely relied upon during concomitant therapy with oxcarbazepine.
Oxtriphylline	The contraceptive increases the effect and toxicity of theophylline
Oxytetracycline	This anti-infectious agent could decrease the effect of the oral contraceptive
Pentobarbital	This product may cause a slight decrease of contraceptive effect
Phenobarbital	This product may cause a slight decrease of contraceptive effect
Phenytoin	This product may cause a slight decrease of contraceptive effect
Piperacillin	This anti-infectious agent could decrease the effect of the oral contraceptive
Pivampicillin	This anti-infectious agent could decrease the effect of the oral contraceptive
Prednisolone	The estrogenic agent, ethinyl estradiol, may increase the effect of the corticosteroid, prednisolone.
Prednisone	The estrogenic agent, ethinyl estradiol, may increase the effect of corticosteroid, prednisone.
Primidone	This product may cause a slight decrease of contraceptive effect
Raloxifene	Association not recommended
Rifabutin	Rifabutin may decrease the contraceptive effect of ethinyl estradiol. Hormonal contraception should not be solely relied on alone during concomitant therapy with rifabutin.
Rifampin	This product may cause a slight decrease of contraceptive effect
Rifapentine	This product may cause a slight decrease of contraceptive effect
Ritonavir	Ritonavir could decrease the contraceptive efficacy
Rolitetracycline	This anti-infectious agent could decrease the effect of the oral contraceptive
Rufinamide	Rufinamide decreases plasma concentrations of ethinyl estradiol, thus consider therapy modification
Secobarbital	This product may cause a slight decrease of contraceptive effect
St. John's Wort	St. John's Wort could reduce the contraceptive effect
Tacrolimus	Ethinyl estradiol may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Ethinyl estradiol therapy is initiated, discontinued or altered.
Talbutal	This product may cause a slight decrease of contraceptive effect
Tazobactam	This anti-infectious agent could decrease the effect of the oral contraceptive
Tetracycline	This anti-infectious agent could decrease the effect of the oral contraceptive
Theophylline	The contraceptive increases the effect and toxicity of theophylline
Thiopental	Thiopental may decrease the effect of Ethinyl estradiol. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy.
Ticarcillin	This anti-infectious agent could decrease the effect of the oral contraceptive
Tipranavir	Tipranavir, co-administered with Ritonavir, decreases Ethinyl estradiol concentrations. Ethinyl estradiol may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Use an alternate form of contraception or monitor for estrogen deficiency if Ethinyl estradiol is used for hormone replacement therapy.
Tizanidine	Ethinyl estradiol may increase the serum concentration of tizanidine. Monitor for changes in the therapeutic and adverse effects of tizanidine if ethinyl estradiol is initiated, discontinued or dose changed.
Topiramate	Topiramate may decrease the effect of the oral contraceptive, Ethinyl estradiol. An alternate form of contraception should be used during concomitant therapy.
Tretinoin	Oral Tretinoin may decrease the effect of the oral contraceptive, Ethinyl Estradiol. An alternate form of contraception should be used during concomitant therapy.
Troglitazone	Possible loss of contracepitve effect
Ursodeoxycholic acid	Estrogens decreases the effect of ursodiol
Warfarin	Ethinyl estradiol may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if ethinyl estradiol is initiated, discontinued or dose changed.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
3.67

# Experimental_Logs:
-4.3

# Experimental_Water_Solubility:
11.3 mg/L (at 27 °C)

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Ethinyl Estradiol

# HET_ID:
Not Available

# Half_Life:
36 +/- 13 hours

# InChI_Identifier:
InChI=1S/C20H24O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/t16-,17-,18+,19+,20+/m1/s1

# InChI_Key:
InChIKey=BFPYWIDHMRZLRN-SLHNCBLASA-N

# Indication:
For treatment of moderate to severe vasomotor symptoms associated with the menopause, female hypogonadism, prostatic carcinoma-palliative therapy of advanced disease, breast cancer, as an oral contraceptive, and as emergency contraceptive.

# KEGG_Compound_ID:
C07534

# KEGG_Drug_ID:
D00554

# LIMS_Drug_ID:
977

# Mechanism_Of_Action:
Estrogens diffuse into their target cells and interact with a protein receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. This cascade is initiated by initially binding to the estrogen receptors. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH).

# Melting_Point:
183 °C

# Molecular_Weight_Avg:
296.4034

# Molecular_Weight_Mono:
296.177630012

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA449527

# Pharmacology:
Ethinyl estradiol is a synthetic derivative of the natural estrogen estradiol. It is one of two estrogens currently used in oral contraceptive pills. The other, mestranol, is converted to ethinyl estradiol before it is biologically active. Ethinyl estradiol and norethindrone are used together as an oral contraceptive agent.

# Predicted_LogP_Hydrophobicity:
3.63

# Predicted_LogS:
-4.6

# Predicted_Water_Solubility:
6.77e-03 g/l

# Primary_Accession_No:
DB00977

# Protein_Binding:
97%

# PubChem_Compound_ID:
5991

# PubChem_Substance_ID:
46508618

# RxList_Link:
http://www.rxlist.com/cgi/generic/estinyl.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00691

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
17 alpha-Ethinylestradiol
17 alpha-Ethynylestradiol
17 alpha-Ethynyloestradiol
17-ethinyl-3,17-estradiol
17-ethinyl-3,17-oestradiol
17-ethinylestradiol
17alpha-Ethinyl estradiol
17α-ethynylestradiol
Ethinyl-Oestranol
Ethinylestradiol
Ethinylestradiolum [INN-Latin]
Ethinylestriol
Ethinyloestradiol
Ethynyl estradiol
Ethynylestradiol
Ethynyloestradiol
Etinilestradiol [INN-Spanish]

# Synthesis_Reference:
Not Available

# Toxicity:
Oral, mouse LD<sub>50</sub>: 1737 mg/kg. Symptoms of overdose include nausea and vomiting, and withdrawal bleeding may occur in females. The FDA label includes a black box warning that states that combination oral contraceptives with ethinyl estradiol should not be used in women over 35 years old who smoke due to the increased risk of serious cardiovascular side effects.

# Update_Date:
2013-06-19 16:27:56 -0600

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Ethinylestradiol

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP3A4

# Phase_1_Metabolizing_Enzyme_1_ID:
4512

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 3A4

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P08684

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
CYP2C8

# Phase_1_Metabolizing_Enzyme_2_ID:
4924

# Phase_1_Metabolizing_Enzyme_2_Name:
Cytochrome P450 2C8

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Cytochrome P450 2C8
MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDICKSFTNFSKV
YGPVFTVYFGMNPIVVFHGYEAVKEALIDNGEEFSGRGNSPISQRITKGLGIISSNGKRW
KEIRRFSLTTLRNFGMGKRSIEDRVQEEAHCLVEELRKTKASPCDPTFILGCAPCNVICS
VVFQKRFDYKDQNFLTLMKRFNENFRILNSPWIQVCNNFPLLIDCFPGTHNKVLKNVALT
RSYIREKVKEHQASLDVNNPRDFIDCFLIKMEQEKDNQKSEFNIENLVGTVADLFVAGTE
TTSTTLRYGLLLLLKHPEVTAKVQEEIDHVIGRHRSPCMQDRSHMPYTDAVVHEIQRYSD
LVPTGVPHAVTTDTKFRNYLIPKGTTIMALLTSVLHDDKEFPNPNIFDPGHFLDKNGNFK
KSDYFMPFSAGKRICAGEGLARMELFLFLTTILQNFNLKSVDDLKNLNTTAVTKGIVSLP
PSYQICFIPV

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
P10632

# Drug_Target_1_Cellular_Location:
Nucleus

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
17095591	Micevych PE, Chaban V, Ogi J, Dewing P, Lu JK, Sinchak K: Estradiol stimulates progesterone synthesis in hypothalamic astrocyte cultures. Endocrinology. 2007 Feb;148(2):782-9. Epub 2006 Nov 9.
17124377	Garcia-Segura LM, Sanz A, Mendez P: Cross-talk between IGF-I and estradiol in the brain: focus on neuroprotection. Neuroendocrinology. 2006;84(4):275-9. Epub 2006 Nov 23.
17125913	Brama M, Gnessi L, Basciani S, Cerulli N, Politi L, Spera G, Mariani S, Cherubini S, d'Abusco AS, Scandurra R, Migliaccio S: Cadmium induces mitogenic signaling in breast cancer cell by an ERalpha-dependent mechanism. Mol Cell Endocrinol. 2007 Jan 29;264(1-2):102-8. Epub 2006 Nov 27.
17138652	Lehnes K, Winder AD, Alfonso C, Kasid N, Simoneaux M, Summe H, Morgan E, Iann MC, Duncan J, Eagan M, Tavaluc R, Evans CH Jr, Russell R, Wang A, Hu F, Stoica A: The effect of estradiol on in vivo tumorigenesis is modulated by the human epidermal growth factor receptor 2/phosphatidylinositol 3-kinase/Akt1 pathway. Endocrinology. 2007 Mar;148(3):1171-80. Epub 2006 Nov 30.
17142999	Mukai H, Tsurugizawa T, Ogiue-Ikeda M, Murakami G, Hojo Y, Ishii H, Kimoto T, Kawato S: Local neurosteroid production in the hippocampus: influence on synaptic plasticity of memory. Neuroendocrinology. 2006;84(4):255-63. Epub 2006 Dec 1.
19237207	Notch EG, Mayer GD: 17alpha-Ethinylestradiol hinders nucleotide excision repair in zebrafish liver cells. Aquat Toxicol. 2009 Dec 13;95(4):273-8. Epub 2009 Jan 23.
19434891	Bennink HJ: Reprint of Are all estrogens the same? Maturitas. 2008 Sep-Oct;61(1-2):195-201.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
ESR1

# Drug_Target_1_GenBank_ID_Gene:
X03635

# Drug_Target_1_GenBank_ID_Protein:
31234

# Drug_Target_1_GeneCard_ID:
ESR1

# Drug_Target_1_Gene_Name:
ESR1

# Drug_Target_1_Gene_Sequence:
>1788 bp
ATGACCATGACCCTCCACACCAAAGCATCTGGGATGGCCCTACTGCATCAGATCCAAGGG
AACGAGCTGGAGCCCCTGAACCGTCCGCAGCTCAAGATCCCCCTGGAGCGGCCCCTGGGC
GAGGTGTACCTGGACAGCAGCAAGCCCGCCGTGTACAACTACCCCGAGGGCGCCGCCTAC
GAGTTCAACGCCGCGGCCGCCGCCAACGCGCAGGTCTACGGTCAGACCGGCCTCCCCTAC
GGCCCCGGGTCTGAGGCTGCGGCGTTCGGCTCCAACGGCCTGGGGGGTTTCCCCCCACTC
AACAGCGTGTCTCCGAGCCCGCTGATGCTACTGCACCCGCCGCCGCAGCTGTCGCCTTTC
CTGCAGCCCCACGGCCAGCAGGTGCCCTACTACCTGGAGAACGAGCCCAGCGGCTACACG
GTGCGCGAGGCCGGCCCGCCGGCATTCTACAGGCCAAATTCAGATAATCGACGCCAGGGT
GGCAGAGAAAGATTGGCCAGTACCAATGACAAGGGAAGTATGGCTATGGAATCTGCCAAG
GAGACTCGCTACTGTGCAGTGTGCAATGACTATGCTTCAGGCTACCATTATGGAGTCTGG
TCCTGTGAGGGCTGCAAGGCCTTCTTCAAGAGAAGTATTCAAGGACATAACGACTATATG
TGTCCAGCCACCAACCAGTGCACCATTGATAAAAACAGGAGGAAGAGCTGCCAGGCCTGC
CGGCTCCGCAAATGCTACGAAGTGGGAATGATGAAAGGTGGGATACGAAAAGACCGAAGA
GGAGGGAGAATGTTGAAACACAAGCGCCAGAGAGATGATGGGGAGGGCAGGGGTGAAGTG
GGGTCTGCTGGAGACATGAGAGCTGCCAACCTTTGGCCAAGCCCGCTCATGATCAAACGC
TCTAAGAAGAACAGCCTGGCCTTGTCCCTGACGGCCGACCAGATGGTCAGTGCCTTGTTG
GATGCTGAGCCCCCCATACTCTATTCCGAGTATGATCCTACCAGACCCTTCAGTGAAGCT
TCGATGATGGGCTTACTGACCAACCTGGCAGACAGGGAGCTGGTTCACATGATCAACTGG
GCGAAGAGGGTGCCAGGCTTTGTGGATTTGACCCTCCATGATCAGGTCCACCTTCTAGAA
TGTGCCTGGCTAGAGATCCTGATGATTGGTCTCGTCTGGCGCTCCATGGAGCACCCAGTG
AAGCTACTGTTTGCTCCTAACTTGCTCTTGGACAGGAACCAGGGAAAATGTGTAGAGGGC
ATGGTGGAGATCTTCGACATGCTGCTGGCTACATCATCTCGGTTCCGCATGATGAATCTG
CAGGGAGAGGAGTTTGTGTGCCTCAAATCTATTATTTTGCTTAATTCTGGAGTGTACACA
TTTCTGTCCAGCACCCTGAAGTCTCTGGAAGAGAAGGACCATATCCACCGAGTCCTGGAC
AAGATCACAGACACTTTGATCCACCTGATGGCCAAGGCAGGCCTGACCCTGCAGCAGCAG
CACCAGCGGCTGGCCCAGCTCCTCCTCATCCTCTCCCACATCAGGCACATGAGTAACAAA
GGCATGGAGCATCTGTACAGCATGAAGTGCAAGAACGTGGTGCCCCTCTATGACCTGCTG
CTGGAGATGCTGGACGCCCACCGCCTACATGCGCCCACTAGCCGTGGAGGGGCATCCGTG
GAGGAGACGGACCAAAGCCACTTGGCCACTGCGGGCTCTACTTCATCGCATTCCTTGCAA
AAGTATTACATCACGGGGGAGGCAGAGGGTTTCCCTGCCACAGTCTGA

# Drug_Target_1_General_Function:
Involved in transcription factor activity

# Drug_Target_1_General_References:
10359819	Montano MM, Ekena K, Delage-Mourroux R, Chang W, Martini P, Katzenellenbogen BS: An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens. Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6947-52.
10428798	Rogatsky I, Trowbridge JM, Garabedian MJ: Potentiation of human estrogen receptor alpha transcriptional activation through phosphorylation of serines 104 and 106 by the cyclin A-CDK2 complex. J Biol Chem. 1999 Aug 6;274(32):22296-302.
10567404	Lee SK, Anzick SL, Choi JE, Bubendorf L, Guan XY, Jung YK, Kallioniemi OP, Kononen J, Trent JM, Azorsa D, Jhun BH, Cheong JH, Lee YC, Meltzer PS, Lee JW: A nuclear factor, ASC-2, as a cancer-amplified transcriptional coactivator essential for ligand-dependent transactivation by nuclear receptors in vivo. J Biol Chem. 1999 Nov 26;274(48):34283-93.
10619354	Schubert EL, Lee MK, Newman B, King MC: Single nucleotide polymorphisms (SNPs) in the estrogen receptor gene and breast cancer susceptibility. J Steroid Biochem Mol Biol. 1999 Nov;71(1-2):21-7.
11113208	Sauve F, McBroom LD, Gallant J, Moraitis AN, Labrie F, Giguere V: CIA, a novel estrogen receptor coactivator with a bifunctional nuclear receptor interacting determinant. Mol Cell Biol. 2001 Jan;21(1):343-53.
11971969	Shao W, Halachmi S, Brown M: ERAP140, a conserved tissue-specific nuclear receptor coactivator. Mol Cell Biol. 2002 May;22(10):3358-72.
12415108	Wong CW, McNally C, Nickbarg E, Komm BS, Cheskis BJ: Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14783-8. Epub 2002 Nov 1.
14574404	Mungall AJ, Palmer SA, Sims SK, Edwards CA, Ashurst JL, Wilming L, Jones MC, Horton R, Hunt SE, Scott CE, Gilbert JG, Clamp ME, Bethel G, Milne S, Ainscough R, Almeida JP, Ambrose KD, Andrews TD, Ashwell RI, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Barker DJ, Barlow KF, Bates K, Beare DM, Beasley H, Beasley O, Bird CP, Blakey S, Bray-Allen S, Brook J, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Carder C, Carter NP, Chapman JC, Clark SY, Clark G, Clee CM, Clegg S, Cobley V, Collier RE, Collins JE, Colman LK, Corby NR, Coville GJ, Culley KM, Dhami P, Davies J, Dunn M, Earthrowl ME, Ellington AE, Evans KA, Faulkner L, Francis MD, Frankish A, Frankland J, French L, Garner P, Garnett J, Ghori MJ, Gilby LM, Gillson CJ, Glithero RJ, Grafham DV, Grant M, Gribble S, Griffiths C, Griffiths M, Hall R, Halls KS, Hammond S, Harley JL, Hart EA, Heath PD, Heathcott R, Holmes SJ, Howden PJ, Howe KL, Howell GR, Huckle E, Humphray SJ, Humphries MD, Hunt AR, Johnson CM, Joy AA, Kay M, Keenan SJ, Kimberley AM, King A, Laird GK, Langford C, Lawlor S, Leongamornlert DA, Leversha M, Lloyd CR, Lloyd DM, Loveland JE, Lovell J, Martin S, Mashreghi-Mohammadi M, Maslen GL, Matthews L, McCann OT, McLaren SJ, McLay K, McMurray A, Moore MJ, Mullikin JC, Niblett D, Nickerson T, Novik KL, Oliver K, Overton-Larty EK, Parker A, Patel R, Pearce AV, Peck AI, Phillimore B, Phillips S, Plumb RW, Porter KM, Ramsey Y, Ranby SA, Rice CM, Ross MT, Searle SM, Sehra HK, Sheridan E, Skuce CD, Smith S, Smith M, Spraggon L, Squares SL, Steward CA, Sycamore N, Tamlyn-Hall G, Tester J, Theaker AJ, Thomas DW, Thorpe A, Tracey A, Tromans A, Tubby B, Wall M, Wallis JM, West AP, White SS, Whitehead SL, Whittaker H, Wild A, Willey DJ, Wilmer TE, Wood JM, Wray PW, Wyatt JC, Young L, Younger RM, Bentley DR, Coulson A, Durbin R, Hubbard T, Sulston JE, Dunham I, Rogers J, Beck S: The DNA sequence and analysis of human chromosome 6. Nature. 2003 Oct 23;425(6960):805-11.
1577818	Reese JC, Katzenellenbogen BS: Characterization of a temperature-sensitive mutation in the hormone binding domain of the human estrogen receptor. Studies in cell extracts and intact cells and their implications for hormone-dependent transcriptional activation. J Biol Chem. 1992 May 15;267(14):9868-73.
2247153	Schwabe JW, Neuhaus D, Rhodes D: Solution structure of the DNA-binding domain of the oestrogen receptor. Nature. 1990 Nov 29;348(6300):458-61.
2792078	Tora L, Mullick A, Metzger D, Ponglikitmongkol M, Park I, Chambon P: The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties. EMBO J. 1989 Jul;8(7):1981-6.
3753802	Greene GL, Gilna P, Waterfield M, Baker A, Hort Y, Shine J: Sequence and expression of human estrogen receptor complementary DNA. Science. 1986 Mar 7;231(4742):1150-4.
3754034	Green S, Walter P, Kumar V, Krust A, Bornert JM, Argos P, Chambon P: Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature. 1986 Mar 13-19;320(6058):134-9.
7476978	Joel PB, Traish AM, Lannigan DA: Estradiol and phorbol ester cause phosphorylation of serine 118 in the human estrogen receptor. Mol Endocrinol. 1995 Aug;9(8):1041-52.
7539106	Arnold SF, Obourn JD, Jaffe H, Notides AC: Phosphorylation of the human estrogen receptor on tyrosine 537 in vivo and by src family tyrosine kinases in vitro. Mol Endocrinol. 1995 Jan;9(1):24-33.
7838153	Arnold SF, Obourn JD, Jaffe H, Notides AC: Serine 167 is the major estradiol-induced phosphorylation site on the human estrogen receptor. Mol Endocrinol. 1994 Sep;8(9):1208-14.
7916651	Pfeffer U, Fecarotta E, Castagnetta L, Vidali G: Estrogen receptor variant messenger RNA lacking exon 4 in estrogen-responsive human breast cancer cell lines. Cancer Res. 1993 Feb 15;53(4):741-3.
8221895	Schwabe JW, Chapman L, Finch JT, Rhodes D: The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: how receptors discriminate between their response elements. Cell. 1993 Nov 5;75(3):567-78.
8600466	Pink JJ, Wu SQ, Wolf DM, Bilimoria MM, Jordan VC: A novel 80 kDa human estrogen receptor containing a duplication of exons 6 and 7. Nucleic Acids Res. 1996 Mar 1;24(5):962-9.
8961262	McInerney EM, Ince BA, Shapiro DJ, Katzenellenbogen BS: A transcriptionally active estrogen receptor mutant is a novel type of dominant negative inhibitor of estrogen action. Mol Endocrinol. 1996 Dec;10(12):1519-26.
9195227	Anderson TI, Wooster R, Laake K, Collins N, Warren W, Skrede M, Elles R, Tveit KM, Johnston SR, Dowsett M, Olsen AO, Moller P, Stratton MR, Borresen-Dale AL: Screening for ESR mutations in breast and ovarian cancer patients. Hum Mutat. 1997;9(6):531-6.
9338790	Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M: Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 1997 Oct 16;389(6652):753-8.
9600906	Tanenbaum DM, Wang Y, Williams SP, Sigler PB: Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proc Natl Acad Sci U S A. 1998 May 26;95(11):5998-6003.
9619507	Maalouf GJ, Xu W, Smith TF, Mohr SC: Homology model for the ligand-binding domain of the human estrogen receptor. J Biomol Struct Dyn. 1998 Apr;15(5):841-51.
9875847	Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL: The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 1998 Dec 23;95(7):927-37.

# Drug_Target_1_HGNC_ID:
HGNC:3467

# Drug_Target_1_HPRD_ID:
00589

# Drug_Target_1_ID:
136

# Drug_Target_1_Locus:
6q25.1

# Drug_Target_1_Molecular_Weight:
66217

# Drug_Target_1_Name:
Estrogen receptor

# Drug_Target_1_Number_of_Residues:
595

# Drug_Target_1_PDB_ID:
1R5K

# Drug_Target_1_Pathway:
Tamoxifen Pathway	SMP00471

# Drug_Target_1_Pfam_Domain_Function:
PF00104	Hormone_recep
PF00105	zf-C4
PF02159	Oest_recep

# Drug_Target_1_Protein_Sequence:
>Estrogen receptor
MTMTLHTKASGMALLHQIQGNELEPLNRPQLKIPLERPLGEVYLDSSKPAVYNYPEGAAY
EFNAAAAANAQVYGQTGLPYGPGSEAAAFGSNGLGGFPPLNSVSPSPLMLLHPPPQLSPF
LQPHGQQVPYYLENEPSGYTVREAGPPAFYRPNSDNRRQGGRERLASTNDKGSMAMESAK
ETRYCAVCNDYASGYHYGVWSCEGCKAFFKRSIQGHNDYMCPATNQCTIDKNRRKSCQAC
RLRKCYEVGMMKGGIRKDRRGGRMLKHKRQRDDGEGRGEVGSAGDMRAANLWPSPLMIKR
SKKNSLALSLTADQMVSALLDAEPPILYSEYDPTRPFSEASMMGLLTNLADRELVHMINW
AKRVPGFVDLTLHDQVHLLECAWLEILMIGLVWRSMEHPGKLLFAPNLLLDRNQGKCVEG
MVEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSLEEKDHIHRVLD
KITDTLIHLMAKAGLTLQQQHQRLAQLLLILSHIRHMSNKGMEHLYSMKCKNVVPLYDLL
LEMLDAHRLHAPTSRGGASVEETDQSHLATAGSTSSHSLQKYYITGEAEGFPATV

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues

# Drug_Target_1_SwissProt_ID:
P03372

# Drug_Target_1_SwissProt_Name:
ESR1_HUMAN

# Drug_Target_1_Synonyms:
ER
ER-alpha
Estradiol receptor

# Drug_Target_1_Theoretical_pI:
8.14

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Nucleus

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17327420	Xue Y, Moore LB, Orans J, Peng L, Bencharit S, Kliewer SA, Redinbo MR: Crystal structure of the pregnane X receptor-estradiol complex provides insights into endobiotic recognition. Mol Endocrinol. 2007 May;21(5):1028-38. Epub 2007 Feb 27.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
NR1I2

# Drug_Target_2_GenBank_ID_Gene:
AF061056

# Drug_Target_2_GenBank_ID_Protein:
3511138

# Drug_Target_2_GeneCard_ID:
NR1I2

# Drug_Target_2_Gene_Name:
NR1I2

# Drug_Target_2_Gene_Sequence:
>1305 bp
CTGGAGGTGAGACCCAAAGAAAGCTGGAACCATGCTGACTTTGTACACTGTGAGGACACA
GAGTCTGTTCCTGGAAAGCCCAGTGTCAACGCAGATGAGGAAGTCGGAGGTCCCCAAATC
TGCCGTGTATGTGGGGACAAGGCCACTGGCTATCACTTCAATGTCATGACATGTGAAGGA
TGCAAGGGCTTTTTCAGGAGGGCCATGAAACGCAACGCCCGGCTGAGGTGCCCCTTCCGG
AAGGGCGCCTGCGAGATCACCCGGAAGACCCGGCGACAGTGCCAGGCCTGCCGCCTGCGC
AAGTGCCTGGAGAGCGGCATGAAGAAGGAGATGATCATGTCCGACGAGGCCGTGGAGGAG
AGGCGGGCCTTGATCAAGCGGAAGAAAAGTGAACGGACAGGGACTCAGCCACTGGGAGTG
CAGGGGCTGACAGAGGAGCAGCGGATGATGATCAGGGAGCTGATGGACGCTCAGATGAAA
ACCTTTGACACTACCTTCTCCCATTTCAAGAATTTCCGGCTGCCAGGGGTGCTTAGCAGT
GGCTGCGAGTTGCCAGAGTCTCTGCAGGCCCCATCGAGGGAAGAAGCTGCCAAGTGGAGC
CAGGTCCGGAAAGATCTGTGCTCTTTGAAGGTCTCTCTGCAGCTGCGGGGGGAGGATGGC
AGTGTCTGGAACTACAAACCCCCAGCCGACAGTGGCGGGAAAGAGATCTTCTCCCTGCTG
CCCCACATGGCTGACATGTCAACCTACATGTTCAAAGGCATCATCAGCTTTGCCAAAGTC
ATCTCCTACTTCAGGGACTTGCCCATCGAGGACCAGATCTCCCTGCTGAAGGGGGCCGCT
TTCGAGCTGTGTCAACTGAGATTCAACACAGTGTTCAACGCGGAGACTGGAACCTGGGAG
TGTGGCCGGCTGTCCTACTGCTTGGAAGACACTGCAGGTGGCTTCCAGCAACTTCTACTG
GAGCCCATGCTGAAATTCCACTACATGCTGAAGAAGCTGCAGCTGCATGAGGAGGAGTAT
GTGCTGATGCAGGCCATCTCCCTCTTCTCCCCAGACCGCCCAGGTGTGCTGCAGCACCGC
GTGGTGGACCAGCTGCAGGAGCAATTCGCCATTACTCTGAAGTCCTACATTGAATGCAAT
CGGCCCCAGCCTGCTCATAGGTTCTTGTTCCTGAAGATCATGGCTATGCTCACCGAGCTC
CGCAGCATCAATGCTCAGCACACCCAGCGGCTGCTGCGCATCCAGGACATACACCCCTTT
GCTACGCCCCTCATGCAGGAGTTGTTCGGCATCACAGGTAGCTGA

# Drug_Target_2_General_Function:
Involved in transcription factor activity

# Drug_Target_2_General_References:
11408620	Watkins RE, Wisely GB, Moore LB, Collins JL, Lambert MH, Williams SP, Willson TM, Kliewer SA, Redinbo MR: The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science. 2001 Jun 22;292(5525):2329-33. Epub 2001 Jun 14.
11668216	Zhang J, Kuehl P, Green ED, Touchman JW, Watkins PB, Daly A, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Wrighton SA, Hancock M, Kim RB, Strom S, Thummel K, Russell CG, Hudson JR Jr, Schuetz EG, Boguski MS: The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics. 2001 Oct;11(7):555-72.
12606758	Kawana K, Ikuta T, Kobayashi Y, Gotoh O, Takeda K, Kawajiri K: Molecular mechanism of nuclear translocation of an orphan nuclear receptor, SXR. Mol Pharmacol. 2003 Mar;63(3):524-31.
9727070	Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA: The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest. 1998 Sep 1;102(5):1016-23.
9770465	Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L, Sydow-Backman M, Ohlsson R, Postlind H, Blomquist P, Berkenstam A: Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12208-13.
9784494	Blumberg B, Sabbagh W Jr, Juguilon H, Bolado J Jr, van Meter CM, Ong ES, Evans RM: SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev. 1998 Oct 15;12(20):3195-205.

# Drug_Target_2_HGNC_ID:
HGNC:7968

# Drug_Target_2_HPRD_ID:
04346

# Drug_Target_2_ID:
1284

# Drug_Target_2_Locus:
3q12-q13.3

# Drug_Target_2_Molecular_Weight:
49762

# Drug_Target_2_Name:
Nuclear receptor subfamily 1 group I member 2

# Drug_Target_2_Number_of_Residues:
434

# Drug_Target_2_PDB_ID:
1NRL

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00104	Hormone_recep
PF00105	zf-C4

# Drug_Target_2_Protein_Sequence:
>Orphan nuclear receptor PXR
MEVRPKESWNHADFVHCEDTESVPGKPSVNADEEVGGPQICRVCGDKATGYHFNVMTCEG
CKGFFRRAMKRNARLRCPFRKGACEITRKTRRQCQACRLRKCLESGMKKEMIMSDEAVEE
RRALIKRKKSERTGTQPLGVQGLTEEQRMMIRELMDAQMKTFDTTFSHFKNFRLPGVLSS
GCELPESLQAPSREEAAKWSQVRKDLCSLKVSLQLRGEDGSVWNYKPPADSGGKEIFSLL
PHMADMSTYMFKGIISFAKVISYFRDLPIEDQISLLKGAAFELCQLRFNTVFNAETGTWE
CGRLSYCLEDTAGGFQQLLLEPMLKFHYMLKKLQLHEEEYVLMQAISLFSPDRPGVLQHR
VVDQLQEQFAITLKSYIECNRPQPAHRFLFLKIMAMLTELRSINAQHTQRLLRIQDIHPF
ATPLMQELFGITGS

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Orphan receptor; its natural ligand is probably pregnane. Binds to a response element in the CYP3A4 and ABCB1/MDR1 genes promoter. Activates its expression in response to a wide variety of endobiotics and xenobiotics

# Drug_Target_2_SwissProt_ID:
O75469

# Drug_Target_2_SwissProt_Name:
NR1I2_HUMAN

# Drug_Target_2_Synonyms:
Orphan nuclear receptor PAR1
Pregnane X receptor
SXR
Steroid and xenobiotic receptor

# Drug_Target_2_Theoretical_pI:
8.44

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB00977
